#USA #oncology #Orlando, Florida #Canopy #ASH2025

Canopy's Remote Therapeutic Monitoring Platform

At the upcoming American Society of Hematology Annual Meeting (ASH 2025), Canopy, a pioneer in Enterprise AI for Oncology, will be presenting compelling findings on the effectiveness of their EHR-integrated Remote Therapeutic Monitoring (RTM) Platform. The study highlights its significant potential to reduce infection-related hospitalizations among patients undergoing treatment for hematological malignancies.

Study Overview

Conducted with patients currently in treatment for a range of blood cancers, the research utilized Canopy's electronic patient-reported outcomes (ePRO) system. This technology enabled patients to report symptoms, which in turn allowed healthcare providers to monitor their conditions actively. Notably, severe or worsening symptoms triggered direct nurse reviews, which expedited the treatment process. These functionalities make the Canopy RTM system a vital tool for managing patient health proactively.

The results are promising: the study found a notable decrease in infection-related hospitalizations among the patients using the RTM, dropping to 2.6% compared to 4.5% for those not using the tool, which corresponds to a risk reduction ratio of 0.48 (p=0.0147).

Presentation Details

The oral presentation will take place on Saturday, December 6th, from 10:30 AM to 10:45 AM EST in Room W230 of the Orange County Convention Center in Orlando, Florida. Canopy aims to share insights not only on hospitalizations but also related metrics, such as emergency department visits and outpatient antibiotic use, enhancing the understanding of infection risks in this patient demographic.

Lavi Kwiatkowsky, the CEO and founder of Canopy, expressed excitement about the opportunity to present at such a prestigious event. He remarked, “We prioritize scientific validation, and being selected for ASH underscores the impact of our RTM system in improving patient care. By enhancing early symptom detection and subsequent treatment options, we can significantly influence cancer treatment outcomes.”

Additional Insights

In addition to the main presentation, Canopy will also showcase further findings through a poster session later that same day. This will emphasize how tracking patient-reported outcomes in real-world scenarios facilitates a more comprehensive assessment of tolerance to Bruton Tyrosine Kinase inhibitors (BTKi), key treatments for chronic lymphocytic leukemia.

Details for this session are as follows:

• - Abstract Number: abs25-13558
• - Presentation ID: 2768
• - Time: 5:30 PM to 7:30 PM EST
• - Location: West Halls B3-B4

Previously at ASH 2024, Canopy reported a 37% reduction in treatment discontinuation among patients using their RTM platform, alongside improved early detection of treatment-related toxicities. Findings from ASCO 2022 indicated a 22% decrease in emergency room visits per 100 patient months, reinforcing the positive impact of using such technologies in oncology.

About Canopy

Canopy is at the forefront of utilizing Enterprise AI in oncology, providing healthcare practices with a unified platform to streamline care that extends beyond traditional visit schedules. Supporting over 2,000 oncology providers across 500+ care sites in the U.S., Canopy's innovative approach not only identifies patients requiring assistance but also employs AI-driven tools to resolve their issues efficiently. By doing so, Canopy helps establish new reimbursement avenues and enhances patient adherence, toxicity management, and overall care quality.

To learn more about Canopy and its initiatives, visit their website at www.canopycare.us.